NCT00832182 - Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 22, 1999

Primary Completion Date

November 25, 2002

Study Completion Date

November 25, 2002

Conditions

DiabetesDiabetes Mellitus, Type 1

Interventions

DRUG

insulin aspart

Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day

DRUG

insulin NPH

Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day

Trial Locations (10)

1000

Novo Nordisk Investigational Site, Ljubljana

10034

Novo Nordisk Investigational Site, Prague

12821

Novo Nordisk Investigational Site, Prague

52621

Novo Nordisk Investigational Site, Tel Litwinsky

117036

Novo Nordisk Investigational Site, Moscow

119435

Novo Nordisk Investigational Site, Moscow

125315

Novo Nordisk Investigational Site, Moscow

129110

Novo Nordisk Investigational Site, Moscow

194354

Novo Nordisk Investigational Site, Saint Petersburg

10 000

Novo Nordisk Investigational Site, Zagreb